Muhammad Rehan1, Joshua E Raizman2, Etienne Cavalier3, Andrew C Don-Wauchope4, Daniel T Holmes5. 1. Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada. Electronic address: muhammad.rehan@medportal.ca. 2. Department of Pathology and Laboratory Medicine, University of Toronto, Medical Science Building, 1 King's College Circle, Toronto, ON M5S 1A8, Canada. Electronic address: josh.raizman@mail.utoronto.ca. 3. Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, Bât B35, 4000 Liège, Belgium. Electronic address: etienne.cavalier@chu.ulg.ac.be. 4. Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada. Electronic address: donwauc@mcmaster.ca. 5. Department of Pathology and Laboratory Medicine, University of British Columbia, Rm. G227-2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada. Electronic address: dtholmes@mail.ubc.ca.
Abstract
BACKGROUND AND OBJECTIVE: The laboratory has a critical role to play in the screening and diagnosis of primary aldosteronism. This review highlights some of the important analytical considerations and the new developments in the determination of aldosterone and renin. METHODS: The review considered the published literature and clinical practice guidelines in the area of primary aldosteronism. RESULTS: A brief introduction to primary aldosteronism is provided. A detailed description of the pre-analytical, analytical and post-analytical considerations for the laboratory determination of aldosterone, renin and the aldosterone to renin ratio follows. CONCLUSIONS: The lack of internationally accepted standardized methodologies and standard reference material has impeded screening and diagnosis of primary aldosteronism. The development of more accurate and sensitive methods by LC-MS/MS has improved the reliability of aldosterone and renin testing and the availability of commercial chemiluminescent assays may improve the standardization of reporting. Laboratorians need to understand the strengths and weaknesses of their analytical approach and ensure that their interpretative reports are appropriate to their assays.
BACKGROUND AND OBJECTIVE: The laboratory has a critical role to play in the screening and diagnosis of primary aldosteronism. This review highlights some of the important analytical considerations and the new developments in the determination of aldosterone and renin. METHODS: The review considered the published literature and clinical practice guidelines in the area of primary aldosteronism. RESULTS: A brief introduction to primary aldosteronism is provided. A detailed description of the pre-analytical, analytical and post-analytical considerations for the laboratory determination of aldosterone, renin and the aldosterone to renin ratio follows. CONCLUSIONS: The lack of internationally accepted standardized methodologies and standard reference material has impeded screening and diagnosis of primary aldosteronism. The development of more accurate and sensitive methods by LC-MS/MS has improved the reliability of aldosterone and renin testing and the availability of commercial chemiluminescent assays may improve the standardization of reporting. Laboratorians need to understand the strengths and weaknesses of their analytical approach and ensure that their interpretative reports are appropriate to their assays.
Authors: Graeme Eisenhofer; Max Kurlbaum; Mirko Peitzsch; Georgiana Constantinescu; Hanna Remde; Manuel Schulze; Denise Kaden; Lisa Marie Müller; Carmina T Fuss; Sonja Kunz; Sylwia Kołodziejczyk-Kruk; Sven Gruber; Aleksander Prejbisz; Felix Beuschlein; Tracy Ann Williams; Martin Reincke; Jacques W M Lenders; Martin Bidlingmaier Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134
Authors: P M O'Shea; T P Griffin; G A Browne; N Gallagher; J J Brady; M C Dennedy; M Bell; D Wall; M Fitzgibbon Journal: Pract Lab Med Date: 2016-11-13
Authors: Stefan R Bornstein; Bruno Allolio; Wiebke Arlt; Andreas Barthel; Andrew Don-Wauchope; Gary D Hammer; Eystein S Husebye; Deborah P Merke; M Hassan Murad; Constantine A Stratakis; David J Torpy Journal: J Clin Endocrinol Metab Date: 2016-01-13 Impact factor: 5.958
Authors: Elisabeth Fabian; Dietmar Schiller; Andreas Tomaschitz; Cord Langner; Stefan Pilz; Stefan Quasthoff; Reinhard B Raggam; Rainer Schoefl; Guenter J Krejs Journal: Wien Klin Wochenschr Date: 2016-09-28 Impact factor: 1.704
Authors: Marieke S Velema; Evie J M Linssen; Ad R M M Hermus; Hans J M M Groenewoud; Gert-Jan van der Wilt; Antonius E van Herwaarden; Jacques W M Lenders; Henri J L M Timmers; Jaap Deinum Journal: Endocr Connect Date: 2018-12 Impact factor: 3.335
Authors: Angela C Rutledge; Anna Johnston; Dana Bailey; Ronald A Booth; Pamela Edmond; Victor Leung; Kika Veljkovic Journal: Pract Lab Med Date: 2021-04-23